Zevra Therapeutics
Nichol Ochsner serves as the Vice President of Investor Relations and Corporate Communications at Zevra Therapeutics since August 2022, focusing on building the investor relations and communications function for a company dedicated to rare disease therapies. Prior experience includes roles as Executive Vice President at Statera BioPharma, where Nichol established investor relations for a biotech start-up, and Vice President at TherapeuticsMD, facilitating the transition to a commercial organization in women's health. Additional experiences encompass leadership positions at Aralez Pharmaceuticals, Endo International, and various biopharmaceutical companies, all centered on developing and enhancing investor communication strategies. Nichol holds a BA in Pre-Law from West Virginia University.
This person is not in any teams
This person is not in any offices
Zevra Therapeutics
1 followers
We are a rare disease therapeutics company leading with science to make life-changing therapeutics available to patients with significant unmet needs. We involve key thought leaders, physicians, patients, care partners, and advocacy groups in all of our clinical and regulatory development strategies. With a keen understanding that drug development often requires creative solutions, we have the insight and expertise to forge new pathways to success that others have missed. By following the data without bias, our transparent narratives and common-sense perspective have successfully overcome complex development challenges to make much-needed therapies available to patients. Nimble and dauntless, we push boundaries beyond what is thought to be possible and advance new therapies that have the potential to bring meaningful improvement to patients’ lives.